Go to main content

R&D Story

GC Biopharma’s researchers
Continue to rise
To the challenge of saving lives.

Third-Generation Recombinant Factor VIII Treatment for Hemophilia

Greengene F

Greengene F is a third-generation gene recombination therapy for hemophilia A, which was successfully developed by GC Biopharma for the third time in the world, and excellent technological prowess and know-how of GC Biopharma are integrated in this product.P hase 3 clinical trials have been completed in China, and product approval has been obtained in 2021. GC Biopharma is also striving to develop next-generation hemophilia treatments that can treat not only patients with hemophilia A and B but also antibody-producing patients by targeting novel blood coagulation mechanisms. The company will expand its pipelines of blood disorder treatments to expand the domestic market and further increase its global market share by making inroads into the ROW market.

A representative photograph of developing a professional medicine.

World-Class Quality

Plasma Derivatives

GC Biopharma remains committed to improving the products that have already won government and market approval, continuing to improve quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is enjoying growing demand in South America and elsewhere. Currently under Phase 3 clinical trial in the United States, the product is expected to be launched on the American market in a few years.

A Pioneer in the Global Vaccine Market


GC Biopharma secured its own technology to manufacture the world’s third-ever hepatitis B vaccine, Hepavax-B (approved in 1983). GC Biopharma developed the world’s first vaccine for epidemic hemorrhagic fever, Hantavax (approved in 1990), and the world’s second chickenpox vaccine, Suduvax (approved in 1993), and consolidated its position as a vaccine specialist company. Barycela (varicella II vaccine), which has improved product quality and safety compared with Suduvax, obtained domestic approval in 2020, and obtained WHO PQ certification in February 2023. GC Biopharma played a crucial role in protecting the nation from the contagious H1N1 flu virus that swept the world in 2009 by developing and launching GCflu (trivalent seasonal flu vaccine, approved in 2009), Greenflu-S (novel influenza vaccine, approved in 2009) and Greenflu-S plus with immune-boosting properties (approved in 2010).

The trivalent flu vaccine of GC Biopharma obtained WHO PQ (prequalification) certification, which is required to take part in international bidding, for the first time in Asia and fourth time in the world. The quadrivalent flu vaccine, GCflu Quadrivalent (approved in 2015), has added one type of influenza B virus strain to trivalent influenza vaccines to broaden the range of prophylactic vaccination and obtained WHO PQ certification for the first time in South Korea and second time in the world. Furthermore, GC Biopharma launched a Td vaccine (tetanus-diphtheria vaccine, approved in 2016) with local technologies for the first time and is now striving to develop a new combined vaccine (Tdap) that protects against all three infections–tetanus, diphtheria and pertussis. As such, GC Biopharma has a rich pipeline of vaccines against diverse diseases and will continue to make an effort to meet international standards to strengthen its global presence, going beyond domestic approval.

Oncology, Immunology, and Cell Therapy

GC Biopharma succeeded in developing Neulapeg, a treatment for neutropenia, in 2014. Designed as a supplement for immunosuppressant chemotherapy and thereby minimizing the treatment’s side effects, Neulapeg offers a longer half-life than its first-generation product. It has also enabled the Korean medical community to cease importing similar drugs from overseas. In addition, GC Biopharma is working on introducing an innovative antibody production technology. The company continues to research and develop new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.

Restoring Hope to People
with Rare Diseases

Rare Disease Treatments

At GC Biopharma, we believe it our duty to research and develop treatments for rare diseases, which are difficult to make and enjoy little market prospect, but which are crucial to saving lives. The first success in this regard came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder also known as mucopolysaccharidosis (MPS) type-II, in 2012. As the second Hunter syndrome treatment to be developed in the world, Hunterase has helped to lighten the financial burden on Korean patients and families by replacing the expensive imported alternative, and significantly improved quality of life for patients. Under GC Biopharma’s plan to bring this innovative drug to Hunter syndrome patients around the world, it has been introduced into eight South American and North African markets. Recently NDA was submitted in China, and it is currently under clinical trials in many countries as well.

A representative photograph of developing a professional medicine.

Future Strategy

GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Biopharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일